The progressive nature of atrial fibrillation: A rationale for early restoration and maintenance of sinus rhythm

Europace

Volumn 8, Issue 11, 2006, Pages 943-949

  Van Gelder, Isabelle C ^a   Hemels, Martin E W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anti arrhythmic therapy; Atrial fibrillation; Catheter ablation; Normal sinus rhythm

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DOFETILIDE; FLECAINIDE; PROPAFENONE; SOTALOL; WARFARIN;

ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; CHRONOTROPISM; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART PROARRHYTHMIA; HEART RATE; HUMAN; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CLINICAL TRIALS; HEART RATE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33750452728     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eul107     Document Type: Review

References (83)

1. Van Gelder IC, Crijns HJ, Tieleman RG et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996;156:2585-92.
2. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110:1042-6.
3. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-52.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
5. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
6. Packer DL, Bardy GH, Worley SJ et al. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. Am J Cardiol 1986;57:563-70.
7. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703.
8. Stevenson WG, Stevenson LW, Middlekauff HR et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-63.
9. Crijns HJ, Tjeerdsma G, De Kam PJ et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000;21:1238-45.
10. Lüderitz B, Jung W. Quality of life in patients with atrial fibrillation. Arch Intern Med 2000;160:1749-57.
11. Hagens VE, Ranchor AV, Van Sonderen E et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2004;43:241-7.
12. Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72.
13. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92.
14. Tomaselli GF. Rate versus rhythm control - an open and shut case? Heart Drug 2003;3:125-26.
15. Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 2002;155:819-26.
16. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
17. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230-46.
18. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26.
19. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959;58:59-70.
20. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The 'leading circle' concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977;41:9-18.
21. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395-410.
22. Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000;101:194-9.
23. Chen YH, Xu SJ, Bendahhou S et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299:251-4.
24. Yang Y, Xia M, Jin Q et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet 2004;75:899-905.
25. Franz MR, Karasik PL, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: Similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997;30:1785-92.
26. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999;84:776-84.
27. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999;100:87-95.
28. Manning WJ, Silverman DI, Katz SE et al. Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994;23:1535-40.
29. Brundel BJ, Henning RH, Kampinga HH, Van Gelder IC, Crijns HJ. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002;54:315-24.
30. Brundel BJ, Van Gelder IC, Henning RH et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001; 103:684-90.
31. Sparks PB, Mond HG, Vohra JK, Yapanis AG, Grigg LE, Kalman JM. Mechanical remodeling of the left atrium after loss of atrioventricular synchrony. A long-term study in humans. Circulation 1999;100:1714-21.
32. Sparks PB, Mond HG, Vohra JK, Jayaprakash S, Kalman JM. Electrical remodeling of the atria following loss of atrioventricular synchrony: A long-term study in humans. Circulation 1999;100:1894-1900.
33. Verheule S, Wilson E, Everett T, Shanbhag S, Golden C, Olgin J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 2003;107:2615-22.
34. Neuberger HR, Schotten U, Verheule S et al. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 2005;111:30-7.
35. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157-63.
36. Al Khatib SM, Wilkinson WE, Sanders LL, McCarthy EA, Pritchett EL. Observations on the transition from intermittent to permanent atrial fibrillation. Am Heart J 2000;140:142-5.
37. Kato T, Yamashita T, Sagara K, Iinuma H, Fu LT. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Circ J 2004;68:568-72.
38. Kopecky SL, Gersh BJ, McGoon MD et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-74.
39. Kopecky SL, Gersh BJ, McGoon MD et al. Lone atrial fibrillation in elderly persons: A marker for cardiovascular risk. Arch Intern Med 1999;159:1118-22.
40. Kerr CR, Humphries KH, Talajic M et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489-96.
41. Willems R, Wyse DG, Gillis AM. Total atrioventricular nodal ablation increases atrial fibrillation burden in patients with paroxysmal atrial fibrillation despite continuation of antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 2003;14:1296-301.
42. Fuster V, Rydén LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary of a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation)
43. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-32.
44. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
45. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
46. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789-94.
47. Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-6.
48. Hagens VE, Van Veldhuisen DJ, Kamp O et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: Results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm 2005;2:19-24.
49. Dorian P, Paquette M, Newman D et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002;143:984-90.
50. Hsu LF, Jaïs P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83.
51. Van den Berg MP, Van Gelder IC, Van Veldhuisen DJ. Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur J Heart Fail 2002;4:571-5.
52. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574-9.
53. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001;104:292-6.
54. Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13.
55. Rienstra M, Van Gelder IC, Hagens VE, Veeger NJ, Van Veldhuisen DJ, Crijns HJ. Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: A subanalysis of the RACE study. Eur Heart J 2006;27:357-64.
56. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol 2004;43:47-52.
57. Borggrefe M, Breithardt G. Maintenance of sinus rhythm as a therapy goal. Europace 2000;2(Suppl. C):C1-5.
58. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the 'pill-in-the-pocket' approach. N Engl J Med 2004;351:2384-91.
59. Rienstra M, Van Veldhuisen DJ, Hagens VE et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: Data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2005;46:1298-306.
60. Hagens VE, Van Gelder IC, Kamp O et al. Atrial and ventricular remodeling during rhythm control in persistent atrial fibrillation-effects of maintenance of sinus rhythm (Abstract 182). Pacing Clin Electrophysiol 2003;26:974.
61. Wood DL, Hammill SC, Holmes DR, Jr, Osborn MJ, Gersh BJ. Catheter ablation of the atrioventricular conduction system in patients with supraventricular tachycardia. Mayo Clin Proc 1983;58:791-6.
62. Cooper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. N Engl J Med 2002;346:2062-8.
63. Vernooy K, Dijkman B, Cheriex EC, Prinzen FW, Crijns HJ. Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. Am J Cardiol 2006;97:1223-7.
64. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1067-78.
65. Haïssaguerre M, Jaïs P, Shah DC et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000;101:1409-17.
66. Pappone C, Rosanio S, Augello G et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: Outcomes from a controlled non-randomized long-term study. J Am Coll Cardiol 2003;42:185-97.
67. Chen MS, Marrouche NF, Khaykin Y et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004;43:1004-9.
68. Rodriguez LM, Timmermans C, Wellens HJ. Are electrophysiological changes induced by longer lasting atrial fibrillation reversible?: Observations using the atrial defibrillator. Circulation 1999;100:113-6.
69. Tamargo J, Caballero R, Delpon E. Pharmacological approaches in the treatment of atrial fibrillation. Curr Med Chem 2004;11:13-28.
70. Sopher SM, Camm AJ. Atrial fibrillation: Maintenance of sinus rhythm versus rate control. Am J Cardiol 1996;77:24A-37A.
71. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJ. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol 1999;84:147R-51R.
72. Singh BN. Atrial fibrillation: Epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm. J Cardiovasc Pharmacol Ther 2003;8(Suppl. 1):S13-S26.
73. Duker G, Björkman JA, Linhardt G et al. AZD7009 - a new atrial antifibrillatory compound that markedly delays atrial refractoriness in the anaesthetised dog (Abstract 501). Heart Rhythm 2004;1:S159.
74. Carlsson L, Duker G, Linhardt G. AZD7009 - a new atrial antifibrillatory compound that markedly delays atrial refractoriness and possesses low proarrhythmic activity in the anaesthetised rabbit (Abstract P2939). Eur Heart J 2004;6:492.
75. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol 2005;16:329-41.
76. Wu Y, Carlsson L, Liu T, Kowey PR, Yan GX. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol 2005;16:898-904.
77. Goldstein RN, Khrestian C, Carlsson L, Waldo AL. Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004;15:1444-50.
78. Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol 2006;47:123-32.
79. Beatch GN, Shinagawa K, Johnson B et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria (Abstract 702). Pacing Clin Electrophysiol 2002;24:698.
80. Ezrin AM, Grant SM, Bell G et al. A dose-ranging study of RSD1235, a novel antiarrhythmic agent, in healthy volunteers (Abstract 22.10). Pharmacologist 2002;44(Suppl. 1):A15.
81. Hesketh JC, Beatch GN, Ezrin AM et al. Safety of RSD1235 in a rabbit Purkinje fiber model (Abstract 22.12). Pharmacologist 2002; 44(Suppl. 1):A16.
82. Roy D, Rowe BH, Stiell IG et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61.
83. Blaauw Y, Gogelein H, Tieleman RG, Van Hunnik A, Schotten U, Allessie MA. 'Early' class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004;110:1717-24.